Get the Stockscreener App
3.89
9.12%
0.325
After Hours:
3.90
0.010
+0.26%
Pyxis Oncology Inc stock is traded at $3.89, with a volume of 2.23M.
It is up +9.12% in the last 24 hours and up +23.10% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$3.565
Open:
$3.53
24h Volume:
2.23M
Relative Volume:
1.89
Market Cap:
$324.46M
Revenue:
$13.86M
Net Income/Loss:
$-81.74M
P/E Ratio:
-2.984
EPS:
-1.3036
Net Cash Flow:
$-66.98M
1W Performance:
+20.43%
1M Performance:
+23.10%
6M Performance:
+161.07%
1Y Performance:
+141.61%
1-Day Range:
$3.515
$4.05
1-Week Range:
$3.0501
$4.05
52-Week Range:
$1.03
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
3.89 | 260.23M | 13.86M | -81.74M | -66.98M | -1.3036 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
PYXS Rallies As Pyxis Oncology Extends Cash Runway To 2027 - timothysykes.com
PYXS Jumps As Pyxis Oncology Extends Cash Runway, Eyes MICVO Data - timothysykes.com
Pyxis Oncology stock gains on MICVO conference catalysts - AD HOC NEWS
Pyxis Oncology Inc (PYXS) Peer Comparison – Compare with Others - Value Research
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
PYXS Stock Price, Quote & Chart - ChartMill
Pyxis Oncology to Participate in Upcoming Investor Conferences - globenewswire.com
Pyxis Oncology Inc (PYXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology (PYXS) Holds Steady at $3.01 as Consolidation TightensSign of Strength - siam.in
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks
Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat
Pyxis Oncology Releases Q2 2026 Financial Results - AlphaStreet
Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade
Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria
PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView
Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView
Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative
Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times
Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo
Pyxis Oncology (PYXS) Rises 7.4% to $3.04 as Biotech Buying Momentum BuildsQuality Factor - Vinanet
currently "more than watching" heheheh - Moomoo
Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Pyxis Oncology (PYXS) Gains 2.68% as Clinical-Stage Biotech Finds Buying SupportVolume Breakout Ideas - dars.gov.et
Pyxis Oncology Inc (PYXS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pyxis Oncology Inc (PYXS) Stock News Today - TradingKey
Price to earnings forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Price to sales forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology (PYXS) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Pyxis Oncology (NASDAQ:PYXS) Raised to Strong-Buy at Wells Fargo & Company - MarketBeat
PYXS Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pyxis Oncology stock with overweight rating By Investing.com - Investing.com South Africa
Wells Fargo Initiates Pyxis Oncology at Overweight With $12 Price Target - marketscreener.com
Pyxis Oncology (PYXS) Slides 7.67% as Biotech Momentum Fades, Testing Key Support ZoneSuperTrend - vinanet.vn
PYXS|Pyxis Oncology Inc|Price:2.910|Chg%:+0.300 - TradingKey
Pyxis Oncology Inc (PYXS) Balance Sheet - TradingKey
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):